Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,579
  • Shares Outstanding, K 16,952
  • Annual Sales, $ 1,770 K
  • Annual Income, $ 47,760 K
  • 60-Month Beta 0.52
  • Price/Sales 4.64
  • Price/Cash Flow N/A
  • Price/Book 0.77
Trade ACRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.49
  • Most Recent Earnings $-0.08 on 11/08/23
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +84.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6701 +28.34%
on 12/12/23
0.8775 -1.99%
on 01/09/24
+0.1314 (+18.03%)
since 12/08/23
3-Month
0.4250 +102.35%
on 11/14/23
0.8775 -1.99%
on 01/09/24
+0.1905 (+28.45%)
since 10/09/23
52-Week
0.4250 +102.35%
on 11/14/23
2.7800 -69.06%
on 01/13/23
-1.3200 (-60.55%)
since 01/09/23

Most Recent Stories

More News
AcelRx Pharmaceuticals: Q3 Earnings Snapshot

AcelRx Pharmaceuticals: Q3 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals: Q2 Earnings Snapshot

AcelRx Pharmaceuticals: Q2 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx...

ACRX : 0.8600 (+7.50%)
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACRX : 0.8600 (+7.50%)
BVS : 6.38 (-3.77%)
AcelRx Pharmaceuticals: Q1 Earnings Snapshot

AcelRx Pharmaceuticals: Q1 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

3rd Resistance Point 0.9980
2nd Resistance Point 0.9377
1st Resistance Point 0.8989
Last Price 0.8600
1st Support Level 0.7998
2nd Support Level 0.7395
3rd Support Level 0.7007

See More

52-Week High 2.7800
Fibonacci 61.8% 1.8804
Fibonacci 50% 1.6025
Fibonacci 38.2% 1.3246
Last Price 0.8600
52-Week Low 0.4250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar